JP2018501794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501794A5 JP2018501794A5 JP2017533969A JP2017533969A JP2018501794A5 JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5 JP 2017533969 A JP2017533969 A JP 2017533969A JP 2017533969 A JP2017533969 A JP 2017533969A JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- car
- sequence encoding
- spacer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206023A JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201423172 | 2014-12-24 | ||
| GB1423172.4 | 2014-12-24 | ||
| PCT/GB2015/054137 WO2016102965A1 (en) | 2014-12-24 | 2015-12-23 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Division JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501794A JP2018501794A (ja) | 2018-01-25 |
| JP2018501794A5 true JP2018501794A5 (enExample) | 2019-06-20 |
| JP6633081B2 JP6633081B2 (ja) | 2020-01-22 |
Family
ID=55066668
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533969A Active JP6633081B2 (ja) | 2014-12-24 | 2015-12-23 | 細胞 |
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US11091532B2 (enExample) |
| EP (3) | EP3237442B1 (enExample) |
| JP (5) | JP6633081B2 (enExample) |
| KR (6) | KR102376242B1 (enExample) |
| CN (2) | CN114107212A (enExample) |
| AU (5) | AU2015370679C1 (enExample) |
| BR (1) | BR112017013690A2 (enExample) |
| CA (2) | CA3224507A1 (enExample) |
| CL (3) | CL2017001314A1 (enExample) |
| DK (2) | DK3237442T3 (enExample) |
| ES (2) | ES2744910T3 (enExample) |
| FI (1) | FI3560953T3 (enExample) |
| HR (1) | HRP20240357T1 (enExample) |
| HU (2) | HUE066020T2 (enExample) |
| IL (4) | IL301458A (enExample) |
| LT (1) | LT3560953T (enExample) |
| MX (1) | MX2017006233A (enExample) |
| PL (2) | PL3237442T3 (enExample) |
| PT (2) | PT3237442T (enExample) |
| RS (1) | RS65343B1 (enExample) |
| RU (2) | RU2768019C2 (enExample) |
| SG (2) | SG11201704084VA (enExample) |
| SI (1) | SI3560953T1 (enExample) |
| SM (1) | SMT202400134T1 (enExample) |
| WO (1) | WO2016102965A1 (enExample) |
| ZA (1) | ZA201703381B (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| KR102376242B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| EP4134430A1 (en) | 2015-02-06 | 2023-02-15 | National University of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| HK1246317A1 (zh) | 2015-03-05 | 2018-09-07 | Fred Hutchinson Cancer Center | 免疫调节融合蛋白及其用途 |
| HUE059218T2 (hu) * | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| SG10201913682QA (en) | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| MY200337A (en) | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| KR20250072712A (ko) | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| JP2020503015A (ja) * | 2016-12-13 | 2020-01-30 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞 |
| EP3567049A4 (en) * | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| AU2018251206A1 (en) * | 2017-04-14 | 2019-10-31 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| ES2905377T3 (es) * | 2017-04-18 | 2022-04-08 | Autolus Ltd | Célula |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CA3062433A1 (en) * | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN109385402A (zh) * | 2017-08-11 | 2019-02-26 | 上海恒润达生生物科技有限公司 | 一种等比例混合两种靶点cart细胞的制备方法及应用 |
| CN107446937B (zh) * | 2017-09-05 | 2020-12-25 | 深圳华云生物技术有限公司 | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 |
| EP3684408A1 (en) | 2017-09-19 | 2020-07-29 | Massachusetts Institute of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| WO2019079249A1 (en) * | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
| CN108101994B (zh) * | 2018-01-04 | 2020-09-15 | 广东万海细胞生物科技有限公司 | 抗cd19抗体及其应用 |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| BR112020015884A2 (pt) | 2018-02-06 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple |
| JP2021512635A (ja) * | 2018-02-12 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的とするキメラ抗原受容体 |
| CN110157738B (zh) * | 2018-02-13 | 2023-06-27 | 亘喜生物科技（上海）有限公司 | 靶向cd19和cd22的工程化免疫细胞及其应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| US12240870B2 (en) | 2018-02-23 | 2025-03-04 | Purdue Research Foundation | Sequencing method for CAR T cell therapy |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CA3099831A1 (en) * | 2018-05-15 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| CA3100386A1 (en) | 2018-05-23 | 2019-11-28 | National University Of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| CN112334479A (zh) * | 2018-07-13 | 2021-02-05 | 南京传奇生物科技有限公司 | 用于治疗感染性疾病的共受体系统 |
| KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
| JP7557882B2 (ja) | 2018-09-28 | 2024-09-30 | マサチューセッツ インスティテュート オブ テクノロジー | コラーゲンに局在化される免疫調節分子およびその方法 |
| GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
| GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| JP7602475B2 (ja) * | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| SG11202112536UA (en) * | 2019-05-16 | 2021-12-30 | Nanjing Legend Biotech Co Ltd | Engineered immune cells comprising a recognition molecule |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| US20220257757A1 (en) | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| JP2022543658A (ja) | 2019-08-07 | 2022-10-13 | アクアラン セラピューティクス コーポレーション | 抗ｎａｍｐｔ抗体及びその用途 |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| CN110903401A (zh) * | 2019-11-20 | 2020-03-24 | 浙江大学 | 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用 |
| AU2020393912B2 (en) * | 2019-11-26 | 2025-11-20 | Novartis Ag | Chimeric antigen receptors binding BCMA and CD19 and uses thereof |
| PH12022551290A1 (en) | 2019-11-26 | 2023-11-29 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| JP7744914B2 (ja) * | 2020-02-04 | 2025-09-26 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | ハプテン標識細胞によりキメラ抗原受容体ｔ細胞を刺激する方法およびそのための組成物 |
| CN115843255A (zh) * | 2020-03-11 | 2023-03-24 | 约瑟夫卡雷拉斯白血病研究基金会 | 用于治疗b细胞型急性淋巴细胞白血病（b-all）的cd22靶向部分 |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| IL298909A (en) | 2020-06-17 | 2023-02-01 | Janssen Biotech Inc | Materials and methods for the manufacture of pluripotent stem cells |
| IL300001A (en) | 2020-07-24 | 2023-03-01 | Massachusetts Gen Hospital | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| EP4203981A2 (en) * | 2020-08-25 | 2023-07-05 | CytoImmune Therapeutics, Inc. | Bispecific antibody car cell immunotherapy |
| JP2023553419A (ja) | 2020-12-03 | 2023-12-21 | センチュリー セラピューティクス，インコーポレイテッド | 遺伝子操作細胞およびその使用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
| WO2023016554A1 (zh) * | 2021-08-13 | 2023-02-16 | 上海医药集团股份有限公司 | 靶向cd22的抗原结合蛋白及其用途 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| WO2023218381A1 (en) | 2022-05-11 | 2023-11-16 | Autolus Limited | Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia |
| JP2025525612A (ja) | 2022-07-22 | 2025-08-05 | ヤンセン バイオテツク，インコーポレーテツド | エフェクター免疫細胞への遺伝的命令の増強された移入 |
| US20240197780A1 (en) * | 2022-12-19 | 2024-06-20 | Development Center For Biotechnology | Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers |
| AU2024240255A1 (en) * | 2023-03-17 | 2025-10-02 | Cartesian Therapeutics, Inc. | Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors |
| WO2024246526A1 (en) | 2023-05-30 | 2024-12-05 | Autolus Limited | Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia |
| WO2024250037A1 (en) * | 2023-06-02 | 2024-12-05 | Northeastern University | Targeted immune cell therapy utilizing trail and tnf mediated apoptosis |
| WO2025088308A1 (en) | 2023-10-23 | 2025-05-01 | Autolus Limited | Products and methods for treating autoimmune diseases |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025215360A1 (en) | 2024-04-09 | 2025-10-16 | Autolus Limited | Method |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| WO2025250011A1 (en) | 2024-05-29 | 2025-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2299011A1 (fr) | 1975-01-29 | 1976-08-27 | Obert Jean Claude | Generateur d'aerosols de part |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| ATE338124T1 (de) * | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| JP2008501621A (ja) * | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| ES2532124T3 (es) | 2005-12-16 | 2015-03-24 | Amgen Research (Munich) Gmbh | Medios y procedimientos para el tratamiento de enfermedades tumorales |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2768863B1 (en) | 2011-10-20 | 2017-09-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd22 chimeric antigen receptors |
| US9447194B2 (en) * | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| ES2786263T3 (es) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
| MX370148B (es) * | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013335180B2 (en) * | 2012-10-24 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
| AU2014214850C1 (en) * | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| ES2671004T3 (es) | 2013-03-07 | 2018-06-04 | Baylor College Of Medicine | Dirección a CD138 en cáncer |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP4098275A1 (en) | 2013-03-15 | 2022-12-07 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| MX374681B (es) | 2013-05-13 | 2025-03-06 | Cellectis | Receptor quimérico de antígeno específico para cd19 y sus usos. |
| EP3021853A1 (en) | 2013-07-18 | 2016-05-25 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| KR102376242B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507111D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| SG10201913682QA (en) | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| CA3099831A1 (en) | 2018-05-15 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
-
2015
- 2015-12-23 KR KR1020217024458A patent/KR102376242B1/ko active Active
- 2015-12-23 CA CA3224507A patent/CA3224507A1/en active Pending
- 2015-12-23 US US15/529,690 patent/US11091532B2/en active Active
- 2015-12-23 JP JP2017533969A patent/JP6633081B2/ja active Active
- 2015-12-23 HU HUE19172397A patent/HUE066020T2/hu unknown
- 2015-12-23 PL PL15817520T patent/PL3237442T3/pl unknown
- 2015-12-23 RU RU2017121892A patent/RU2768019C2/ru active
- 2015-12-23 MX MX2017006233A patent/MX2017006233A/es active IP Right Grant
- 2015-12-23 LT LTEP19172397.2T patent/LT3560953T/lt unknown
- 2015-12-23 EP EP15817520.8A patent/EP3237442B1/en not_active Revoked
- 2015-12-23 EP EP19172397.2A patent/EP3560953B1/en active Active
- 2015-12-23 KR KR1020227031979A patent/KR20220129684A/ko not_active Ceased
- 2015-12-23 HU HUE15817520A patent/HUE046262T2/hu unknown
- 2015-12-23 KR KR1020197038792A patent/KR20200003939A/ko not_active Ceased
- 2015-12-23 IL IL301458A patent/IL301458A/en unknown
- 2015-12-23 SI SI201531999T patent/SI3560953T1/sl unknown
- 2015-12-23 KR KR1020177019393A patent/KR102085349B1/ko active Active
- 2015-12-23 HR HRP20240357TT patent/HRP20240357T1/hr unknown
- 2015-12-23 CN CN202111208410.1A patent/CN114107212A/zh active Pending
- 2015-12-23 SG SG11201704084VA patent/SG11201704084VA/en unknown
- 2015-12-23 RU RU2022102250A patent/RU2022102250A/ru unknown
- 2015-12-23 KR KR1020237036909A patent/KR20230152824A/ko active Pending
- 2015-12-23 PT PT15817520T patent/PT3237442T/pt unknown
- 2015-12-23 AU AU2015370679A patent/AU2015370679C1/en active Active
- 2015-12-23 ES ES15817520T patent/ES2744910T3/es active Active
- 2015-12-23 RS RS20240357A patent/RS65343B1/sr unknown
- 2015-12-23 DK DK15817520.8T patent/DK3237442T3/da active
- 2015-12-23 FI FIEP19172397.2T patent/FI3560953T3/fi active
- 2015-12-23 CA CA2970440A patent/CA2970440A1/en active Pending
- 2015-12-23 BR BR112017013690-2A patent/BR112017013690A2/pt not_active Application Discontinuation
- 2015-12-23 EP EP23217769.1A patent/EP4368704A3/en active Pending
- 2015-12-23 IL IL274903A patent/IL274903B/en unknown
- 2015-12-23 SM SM20240134T patent/SMT202400134T1/it unknown
- 2015-12-23 PL PL19172397.2T patent/PL3560953T3/pl unknown
- 2015-12-23 DK DK19172397.2T patent/DK3560953T5/da active
- 2015-12-23 KR KR1020217024459A patent/KR102376244B1/ko active Active
- 2015-12-23 ES ES19172397T patent/ES2976197T3/es active Active
- 2015-12-23 SG SG10202111107RA patent/SG10202111107RA/en unknown
- 2015-12-23 WO PCT/GB2015/054137 patent/WO2016102965A1/en not_active Ceased
- 2015-12-23 CN CN201580065695.4A patent/CN107002045B/zh active Active
- 2015-12-23 PT PT191723972T patent/PT3560953T/pt unknown
- 2015-12-23 IL IL292508A patent/IL292508B2/en unknown
-
2017
- 2017-05-10 IL IL252208A patent/IL252208B/en unknown
- 2017-05-16 ZA ZA2017/03381A patent/ZA201703381B/en unknown
- 2017-05-23 CL CL2017001314A patent/CL2017001314A1/es unknown
- 2017-06-23 US US15/631,948 patent/US10098926B2/en active Active
- 2017-06-23 US US15/632,119 patent/US10174099B2/en active Active
-
2018
- 2018-06-29 US US16/024,445 patent/US10981970B2/en active Active
- 2018-11-13 CL CL2018003217A patent/CL2018003217A1/es unknown
- 2018-11-13 CL CL2018003216A patent/CL2018003216A1/es unknown
- 2018-12-06 US US16/211,538 patent/US11034750B2/en active Active
-
2019
- 2019-11-14 JP JP2019206023A patent/JP6909844B2/ja active Active
-
2020
- 2020-02-07 US US16/785,467 patent/US20200181232A1/en not_active Abandoned
- 2020-08-06 AU AU2020213352A patent/AU2020213352B2/en active Active
- 2020-12-01 JP JP2020199333A patent/JP7514746B2/ja active Active
-
2021
- 2021-10-19 JP JP2021170769A patent/JP2022002546A/ja not_active Withdrawn
-
2022
- 2022-07-12 AU AU2022205170A patent/AU2022205170B2/en active Active
- 2022-07-12 AU AU2022205169A patent/AU2022205169B2/en active Active
-
2023
- 2023-01-24 US US18/158,754 patent/US12398194B2/en active Active
-
2024
- 2024-03-05 JP JP2024032851A patent/JP2024055976A/ja active Pending
- 2024-12-10 AU AU2024278248A patent/AU2024278248A1/en active Pending
-
2025
- 2025-07-25 US US19/281,399 patent/US20250353893A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501794A5 (enExample) | ||
| RU2017121892A (ru) | Клетка | |
| JP7578938B2 (ja) | Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用 | |
| JP2016538855A5 (enExample) | ||
| EP3847195B1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| JP2017500869A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| JP2017508466A5 (enExample) | ||
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| CN108138148B (zh) | T细胞的激活和扩增 | |
| JP2018508215A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2016538854A5 (enExample) | ||
| BR112021008082A2 (pt) | terapia contra o câncer com células imunitárias anti-liv1 | |
| CN110938148A (zh) | 靶向cd19和cd22嵌合抗原受体 | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| CN110950957B (zh) | 可结合ctla4的多肽及其应用 | |
| KR20230025655A (ko) | 암 치료용 조성물 및 방법 | |
| CN108484778B (zh) | 人源化ghr106单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 | |
| EP3912992A1 (en) | Car library and production method for scfv | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| CN120500501A (zh) | 用于治疗癌症的细胞和组合物 | |
| CN110950956B (zh) | 可结合pd1的多肽及其应用 | |
| EP4656659A1 (en) | Modified fc-engagers for treating immune diseases |